Skip to main content

Table 1 Baseline clinical characteristics and post-anti-PD-1 outcomes

From: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

Patient no. 1 2 3 4 5
Age (years) 54 40 41 38 35
Sex M F F M F
ECOG performance status 0 2 1 0 2
Diagnosis/stage DLBCL/IV DLBCL/IV DLBCL/III DLBCL/IV DLBCL/III
Disease status1 Relapsed Primary refractory Primary refractory Relapsed Primary refractory
Target lesion Bilateral parotid nodule Bone marrow, spleen, lymph nodes (9 regions) Lymph nodes (2 regions) Bone, lymph node Lymph node
Prior system regimens RCHOP × 5, RDICE × 3, RGEMOX × 9, RMTX × 2, RAD × 6, BEACOPP × 2 RCHOP × 8, DHAP × 4, CART19 CHOPE × 4, RDICE × 6, RDHAP × 4, IR × 2 RCHOPE × 2, ABVD × 3, DICE × 4, ESHAP × 7, BEAM × 2, R2 × 6 REPOCH × 8, GEMOX × 2
Prior RT Yes No No No No
Prior ASCT Yes No No No No
Prior CD19/CD20 CAR-T Yes Yes Yes Yes Yes
 Best response CR CR PR CR PD
 Final response PD PD PD PD PD
 PFS (months) 6 6 5 3 3
Percentage of PD-L1+ expression2 0 0 30% 70% 0
Percentage of PD-L1+ expression3 30% 0 40% 80% 0
Percentage of PD-1+ expression2 0 0 20% 0 0
Percentage of PD-1+ expression3 80% 5% 60% 60% 0
Anti-PD-1 therapy      
 Antibody type (treatment cycle) Sintilimab (12) Camrelizumab (1) Sintilimab (5) Camrelizumab (24) Sintilimab
(2)
 Best response CR PD PR CR PD
 Final response PD PD PD CR PD
 PFS (months) 10.1 0.63 3.3 21.8 1
 OS (months) NE 16.2 NE NE 15.6
 TrAE (grade) Increased transaminase (1) None Fever (2), leukocytopenia (2) Fever (1), rash (1) None
  1. ASCT, autologous stem-cell transplantation; ABVD, doxorubicin, bleomycin, vindesine, dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vindesine, procarbazine, prednisone; BEAM, carmustine, etoposide, cytarabine, melphalan; CHOPE, cyclophosphamide, vindesine, doxorubicin, etoposide, prednisone; DHAP, cisplatin, cytarabine, dexamethasone; ESHAP, rituximab, etoposide, vindesine, doxorubicin, cyclophosphamide, prednisone; GEMOX, gemcitabine, oxaliplatin; RCHOP, rituximab, cyclophosphamide, vindesine, doxorubicin, prednisone; RMTX, rituximab, methotrexate; RAD, rituximab, cytosine arabinoside, dexamethasone; RDHAP, rituximab, cisplatin, cytarabine, dexamethasone; RDICE, rituximab, ifosfamide, cisplatin, etoposide, dexamethasone; REPOCH, rituximab, etoposide, vindesine, doxorubicin, cyclophosphamide, prednisone; RGEMOX, rituximab, gemcitabine, oxaliplatin; RFC, rituximab, fludarabine, cyclophosphamide; R2, rituximab combined with lenalidomide; DLBCL, diffuse large B cell lymphoma; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B cell; PFS, progression-free survival; TrAE, treatment-related adverse events
  2. 1Primary refractory, non-response or relapse within 3 months of frontline therapy
  3. 2These data were collected prior to CART19/20 therapy
  4. 3These data were collected after failure of CART19/20 therapy